Pascal Heberling

Directeur/Membre du Conseil chez Travecta Therapeutics Pte Ltd.

Profil

Pascal is Co-Head of Europe and a Partner at 65 Equity Partners, based in London.
Pascal has over two decades private equity investing experience, latterly at BC Partners, where he was a Partner focusing on healthcare, and where he led the firm’s latest investment in CeramTec.
Prior to that, Pascal spent over six years at the Abu Dhabi Investment Authority (ADIA), in its private equity department, as Head of Healthcare and a member of its Executive Committee.
During this time, Pascal led several investments including Galderma (Nestlé Skin Health), Pharmaceutical Product Development (PPD), and Moderna.
Previously, Pascal spent twelve years at Cinven, including nine years as a Partner, and where he played an integral role in a series of successful investments including Spire Healthcare, Numéricable, MediMedia, and Springer Science (today known as Springer Nature).
He began his career in the mergers and acquisitions group of Merrill Lynch in London.
He has served on numerous boards in his various roles.
Pascal is trilingual in English, French and German.
He graduated summa cum laude from the Institut d’Études Politiques de Paris (Sciences Po) and holds an MA and an MBA from the University of Toronto (dean’s list).

Postes actifs de Pascal Heberling

Sociétés	Poste	Début
Travecta Therapeutics Pte Ltd.	Directeur/Membre du Conseil	27/10/2021
65 Equity Partners Management (UK) Ltd.	Private Equity Investor	01/09/2023
65 Equity Partners Pte Ltd.	Private Equity Investor	01/08/2023

Anciens postes connus de Pascal Heberling

Sociétés	Poste	Fin
Abu Dhabi Investment Authority (Private Equity)	Private Equity Investor	01/04/2020
Cinven Group Ltd.	Private Equity Investor	31/12/2012
Morfind 2025 Ltd.	Directeur/Membre du Conseil	31/12/2012
Spire Healthcare Holdings 3 Ltd.	Directeur/Membre du Conseil	20/03/2008
Merrill Lynch International	Private Equity Investor	01/03/2001